Setmelanotide is an FDA-approved agonist of MC4R for adults and children aged 6 years and older diagnosed with monogenic obesity linked to specific unbenign genetic variants of POMC, PCSK1, or LEPR or those with Bardet-Biedl syndrome [13,15]. The gene discussed is MC4R; the disease is obesity disorder.